Drugs / conjugated equine estrogen
conjugated equine estrogen
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04103476 | Apr 2021 → Oct 2026 expected | atherosclerosis, subjective cognitive decline | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02838576 | Mar 2017 → Dec 2019 | arthropathy | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 44 trials · 1 missed | ||||||
| Phase 4 | NCT06479720 | Jun 2022 → Jun 2026 overdue | overactive bladder | Mackay Memorial Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06197295 | Jun 2022 → Jun 2026 overdue | overactive bladder | Mackay Memorial Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02869165 | Jan 2017 → Jun 2018 | postmenopausal atrophic vaginitis, urinary tract infection | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT00169299 | Jun 2001 → Sep 2004 | — | Kaiser Permanente | Unknown | Missed primary |
| Phase not applicable2 trials | ||||||
| — | NCT00249847 | Oct 2005 → Jul 2007 | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00061711 | Jul 2000 → Dec 2005 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00420342 Comparator | Jan 2007 → Sep 2008 | hypertensive disorder | Bayer | Completed | Missed primary |
| Phase 3 | NCT03097120 Comparator | Jan 1995 → Jan 2001 | heart disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | conjugated equine estrogen | “A total of 360 postmenopausal women with a uterus who are within 6 years of menopause and 45-59 years of age and without clinical cardiovascular disease and diabetes mellitus...” NCT04103476 ↗9“1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)” NCT00420342 ↗ “conjugated equine estrogen 0.625 mg +/- 2.5 mg medroxyprogesterone acetate” PMID 16186076 ↗ Oct 2005 “Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg” NCT06197295 ↗ “Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).” NCT06479720 ↗ |
| Known as | CEE | “vaginal conjugated equine estrogen (CEE) 0.625 mg” NCT06197295 ↗ |
| Known as | Premarin | “The primary objective is to describe the bacterial communities associated in the vagina and urine of postmenopausal women receiving treatment for genitourinary syndrome of...” NCT02869165 ↗1“Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).” NCT06479720 ↗ |
| Action | Inhibit | “both estrogen and SSRI down regulate the serotonin transporter” NCT00249847 ↗ |
| Route | Oral | “0.625 mg tablet, orally, every day for 4 weeks” NCT00249847 ↗ |